Drug Trial Radar · NCT04150497
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Actual
Start
Oct 14, 2019
Primary completion
Sep 16, 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Cellectis S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
UCART22Biological
Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
CLLS52Biological
A monoclonal antibody that recognizes a CD52 antigen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletionTime frame: 24 months
- Percentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committeeTime frame: Within 3 months at Day 28, Day 56, Day 84
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
Children's of Alabama
Birmingham, Alabama
University of California Los Angeles (UCLA)
Los Angeles, California
UCSF Benioff Children's Hospital
San Francisco, California
UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, Colorado
SCRI - Colorado Blood Cancer Institute
Denver, Colorado
University of Illinois Medical Center
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
SCRI - TriStar Centennial Medical Center
Nashville, Tennessee
SCRI - St. David's South Austin Medical Center
Austin, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Methodist Hospital - San Antonio
San Antonio, Texas
University of Wisconsin - Madison
Madison, Wisconsin
Centre Hospitalier Universitaire Nantes - Hôtel Dieu
Nantes, France
Hôpital Saint-Louis
Paris, France
Hôpital Robert-Debré AP-HP
Paris, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Hôpital Pontchaillou
Rennes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.